One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

Neil Abdollahian net worth and biography

Neil Abdollahian Biography and Net Worth

Insider of Cidara Therapeutics

Mr. Abdollahian’s career has been focused on building companies through strategic and transformational transactions totaling over $2 billion in value. Prior to joining Cidara in 2016, Mr. Abdollahian was Managing Director of Clarity Point Partners, a strategic advisory firm focused on providing corporate development initiatives including product acquisitions and licensing for a number of biopharmaceutical companies. From 2008 to 2013, he served as Vice President of Corporate Development at Trius Therapeutics, where he led the corporate partnering initiatives that resulted in the Asia-Pacific and emerging markets strategic partnership with Bayer Healthcare, and ultimately, the acquisition by Cubist Pharmaceuticals in 2013. In 2008, Mr. Abdollahian served as Director of Special Projects in a biopharmaceutical focused investment bank in Sydney, Australia, and from 2001 to 2007, he held various business development positions focused on closing high-value transactions while at Avanir Pharmaceuticals, Isis Pharmaceuticals and Neurogen Corporation. Mr. Abdollahian holds an MBA from Pepperdine University, an M.S. in the biomedical sciences from the University of New Mexico Medical School and a B.S. in biology from the George Washington University.

What is Neil Abdollahian's net worth?: The estimated net worth of Neil Abdollahian is at least $40,027.68 as of January 5th, 2021. Mr. Abdollahian owns 55,440 shares of Cidara Therapeutics stock worth more than $40,028 as of April 19th. This net worth estimate does not reflect any other assets that Mr. Abdollahian may own. Learn More about Neil Abdollahian's net worth.
How do I contact Neil Abdollahian?: The corporate mailing address for Mr. Abdollahian and other Cidara Therapeutics executives is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. Cidara Therapeutics can also be reached via phone at (858) 752-6170 and via email at [email protected]. Learn More on Neil Abdollahian's contact information.
Has Neil Abdollahian been buying or selling shares of Cidara Therapeutics?: Neil Abdollahian has not been actively trading shares of Cidara Therapeutics over the course of the past ninety days. Most recently, Neil Abdollahian sold 1,469 shares of the business's stock in a transaction on Thursday, April 1st. The shares were sold at an average price of $2.66, for a transaction totalling $3,907.54. Following the completion of the sale, the insider now directly owns 55,440 shares of the company's stock, valued at $147,470.40. Learn More on Neil Abdollahian's trading history.
Who are Cidara Therapeutics' active insiders?: Cidara Therapeutics' insider roster includes Neil Abdollahian (Insider), Paul Daruwala (COO), Timothy Franson (Director), Brady Johnson (VP), Jessica Oien (General Counsel), Preetam Shah (CFO), Jeffrey Stein (CEO), and Leslie Tari (Insider). Learn More on Cidara Therapeutics' active insiders.
Are insiders buying or selling shares of Cidara Therapeutics?: In the last twelve months, Cidara Therapeutics insiders bought shares 2 times. They purchased a total of 60,000 shares worth more than $57,700.00. In the last twelve months, insiders at the biotechnology company sold shares 4 times. They sold a total of 78,902 shares worth more than $58,035.66. The most recent insider tranaction occured on March, 11th when insider Leslie Tari sold 21,029 shares worth more than $14,089.43. Insiders at Cidara Therapeutics own 7.4% of the company. Learn More about insider trades at Cidara Therapeutics.
Information on this page was last updated on 3/11/2024.

Neil Abdollahian Insider Trading History at Cidara Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2021	Sell	1,469	$2.66	$3,907.54	55,440
1/5/2021	Sell	2,868	$2.06	$5,908.08	55,440
1/3/2020	Sell	2,340	$3.42	$8,002.80	53,532
10/1/2019	Sell	7,284	$1.98	$14,422.32	49,588
3/8/2019	Sell	2,300	$2.44	$5,612.00	30,472

Neil Abdollahian Buying and Selling Activity at Cidara Therapeutics

Cidara Therapeutics Company Overview

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Today's Range

Now: $0.68

$0.68

$0.74

50 Day Range

MA: $0.78

$0.64

$1.16

2 Week Range

Now: $0.68

$0.59

$1.48

Volume

352,272 shs

Average Volume

653,623 shs

Market Capitalization

$61.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98

Strange new buyer driving up gold

From Stansberry Research | Ad